Compare Quest Diagnostics Inc (DGX) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Inovio Pharmaceuticals Inc — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M). The key difference: Quest Diagnostics Inc is far larger — about 227.1× Inovio Pharmaceuticals Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| DGX | INO | |
|---|---|---|
Market Cap | $25.48B | $112.19M |
Volume | 941,866 | 3,201,278 |
Sector | Health | Health |
52-Week High | $247.45 | $2.60 |
52-Week Low | $173.49 | $0.66 |
Typical Hold Time | 56 Days | 43 Days |
Enterprise Value | $31.23B | $83.51M |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
INO trades at $1.09, down 5.63% today, with a bearish technical outlook and negative financial metrics including a net income margin of -130,000% and ROE of -409.87%. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, though recent earnings have beaten expectations. Key near-term catalyst is the FDA decision on INO-3107 by October 30, 2026.
Despite analyst consensus favoring Buy ratings (58.83%) with a $2.75 price target, INO carries high risk due to persistent cash burn, negative profitability, and dependency on regulatory approvals. The stock offers speculative upside if INO-3107 gains approval but remains vulnerable to further dilution and operational setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
